Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nucleoredoxin (NXN)
- Target
- NXN
- Molecular classification
- Enzyme (specifically, oxidoreductase), Thioredoxin family protein
01
Overview
Nucleoredoxin (NXN) is a thiol-oxidoreductase enzyme of the thioredoxin family ubiquitously expressed in mammalian cells, shuttling between the cytosol and nucleus. Its redox-dependent interactions regulate signaling pathways such as WNT/β-catenin (via disheveled/DVL), Toll-like receptor 4/MYD88/NF-κB, and protein phosphatase 2A (PP2A). NXN participates in critical processes including cell cycle control, cell proliferation, neuronal development, glycolysis, cytoskeletal regulation, immune responses, and organogenesis. Dysregulation or genetic variants of NXN are implicated in cancer, metabolic and neurodegenerative diseases, and other systemic pathologies. As a central hub for cellular redox signaling, NXN is an important candidate for therapeutic targeting and fundamental cell biology research
- Other names
- NucleoredoxinNXNNRXFLJ12614RRS2TRG-4nucleoredoxin 1
02
Mechanism of action
Not applicable; no drugs are known to directly target NXN, but modulation of its oxidoreductase activity could theoretically impact cellular redox signaling and its downstream effects
03
Biological functions
Redox regulationSignal transductionCell proliferationCell cycle progressionGlycolysisInnate immunity and inflammationNeuronal plasticityProtein transport into endoplasmic reticulumMotility and contraction
04
Disease associations
CancerLiver disease (alcoholic and polycystic)Liver fibrogenesisObesityRobinow syndromeDiabetes mellitusAlzheimer’s diseaseRetinitis pigmentosa
05
Safety considerations
As NXN is a master regulator of cellular redox homeostasis, systemic inhibition or activation could disrupt redox balance, potentially affecting vital signaling pathways and leading to adverse effects or unexpected toxicity in targeted therapies
06
Interacting drugs
None reported in the literature; as of now, there are no approved drugs or clinical candidates specifically targeting Nucleoredoxin
07
Biomarkers
None specifically validated for patient selection or efficacy monitoring in clinical use; however, altered NXN expression or activity might serve as research biomarkers for redox imbalance or related pathologies
Beyond the preview
Go deeper on Nucleoredoxin (NXN).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nucleoredoxin (NXN).